LSMD was nominally statistically significant ( P < 0.05 ) for levomilnacipran ER versus placebo in 5 domains ( General Health [ 2.44 ; P = 0.0010 ] , Vitality [ 2.48 ; P = 0.0307 ] , Social Functioning [ 3.25 ; P = 0.0097 ] , Role-Emotional [ 3.38 ; P = 0.0078 ] , Mental Health [ 4.34 ; P = 0.0005 ] ) ; changes in Vitality , Social Functioning , and Mental Health exceeded MID .